Last week, Sonoma Biotherapeutics announced it raised $265M to expand both its Seattle and San Francisco operations.
One of the many perks of having a lab in two major life science clusters is the opportunities it provides for Sonoma to move forward with their research while continuing to grow their manufacturing capabilities.
“You can’t build a world-class biotech in a vacuum,” said Kathryn O’Driscoll, chief people officer for Zymeworks. It requires “the power of community and expertise, and there’s a lot of that in the Pacific Northwest.”